User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

7422

Interactions with Platform & by Email *

INTERACTIONS

1039

Unique # Participated *

PARTICIPANTS

223

Responses Validated *

VALIDATIONS

42

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Robust Growth Ahead for Myeloma Therapeutics Market.....II-4
Multiple Myeloma: A Second Most Common Hematological Cancer.....II-4
1$100
   Table 1: Global Multiple Myeloma Disease Statistics: 2010 (includes corresponding Graph/Chart).....II-5

Table 2: Global Multiple Myeloma Patient Population in Thousands under Treatment by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-5
1$350
   Table 3: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Market Share Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis, Celgene, and Others (includes corresponding Graph/Chart).....II-6
US Remains the Largest Market; Rest of World to Spearhead Growth.....II-6
1$350
   The Myeloma Drug Domain.....II-7
Table 4: Annual Revenues of Select Multiple Myeloma Drugs Worldwide: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart).....II-7
Revlimid Outshines Other Leading Drugs.....II-7
1$350
   Velcade – Still the Most Superior in terms of Survival Rate.....II-8
Table 5: Sales of Velcade in the US and Rest of World: 2008 & 2009 (In US$ Million) (includes corresponding Graph/Chart).....II-8
Subcutaneous Infusion – A Refuge for Velcade from Nueropathy?.....II-8
1$350
   Unmet Needs Drive Further Innovation in the Therapeutic Area.....II-9
Promising Drugs on the Anvil, Potential Market Remains Uncertain.....II-9
Revlimid – A Key Revenue Generator for Celgene.....II-9
1$100
   Table 6: Sales of Revlimid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart).....II-10

Table 7: Sales of Thalomid in the US and Rest of World: 2009 & 2010 (In US$ Million) (includes corresponding Graph/Chart).....II-10
1$350
   Doxil Regains Sales Momentum.....II-11
Treatment Therapies: Move Up the Learning Curve.....II-11
Risk-Adapted Therapy: The New Norm of Future Treatment.....II-11
1$100
   New Generation Drugs in the Arsenal Against Multiple Myeloma.....II-12
Revlimid® (lenalidomide).....II-12
Velcade® (bortezomib).....II-12
Thalomid® (thalidomide).....II-12
1$100
   Doxil (liposomal doxorubicin).....II-13
Alkeran (melphalan).....II-13
Trisenox® (arsenic trioxide).....II-13
Select Promising Pipeline Drugs.....II-13
Carfilzomib (Onyx Pharmaceuticals).....II-13
1$100
   Phase II Results of Carfilzomib.....II-14
Pomalidomide (Celgene).....II-14
1$100
   Noteworthy Issues Related to Major Drugs: An Evaluation of Pros and Cons.....II-15
Revlimid Overtakes Thalomid: Why?.....II-15
How Effective Will Thalomid Be in the 3rd Line Setting? Skepticism Overflows .....II-15
Revlimid Impedes Stem Cell Harvesting!!: What’s the Truth?.....II-15
1$100
   Other Trends & Issues.....II-16
Approval of New Generation Drugs Push the Market Into the Bulge Bracket.....II-16
Growth Fundamentals Get Stronger.....II-16
Multidrug Resistance: A Challenge to Reckon With.....II-16
Gene Therapy Exudes Hope.....II-16
1$100
   Focus on Select Mid- and Late-Stage Clinical Trials in Multiple Myeloma.....II-17
Lenalidomide versus Placebo Maintenance Treatment post Single AHSCT for
  Myeloma.....II-17
Lenalidomide Maintenance Therapy Post Stem Cell Transplantation for Myeloma.....II-17
1$100
   Doxorubicin + Bortezomib + Dexamethasone versus VAD Ensued by High-Dose Melphalan and
  Maintenance with Thalidomide/Bortezomib in Newly Diagnosed MM Patients ......II-18
Weekly Bortezomib Maintenance Therapy Following Bortezomib-based Induction Therapy in
  Recently Diagnosed, Aged MM Sufferers .......II-18
Lenalidomide in Combination with Prednisone and Melphalan in Recently Diagnosed
  Patients Above 65 years of Age ......II-18
1$100
   Bortezomib + Prednisone + Melphalan, and Thalidomide Ensued by Thalidomide +
  Bortezomib Maintenance for Preliminary Treatment of Aged MM Patients.....II-19
Lenalidomide + Dexamethasone + Carfilzomib in Recently Diagnosed Multiple
  Myeloma.....II-19
1$100
   Carfilzomib in Refractory and Relapsed MM Setting.....II-20
Carfilzomib as Standalone Therapy in Relapsed or Refractory MM.....II-20
Combination of Vorinostat and Lenalidomide + Bortezomib in Relapsed/Refractory
  Multiple Myeloma.....II-20
1$100
   Carfilzomib in Refractory/Relapsed MM Patients (for Long-Term Tolerability and
  Treatment).....II-21
Multiple Myeloma Drugs In Pipeline in the Us As of the Year 2008.....II-21
Phase III Drugs in Pipeline.....II-21
2$200
   Phase II Drugs in Pipeline.....II-237$700
   Phase I Drugs in Pipeline.....II-305$500
   Hematological Cancer Therapies: A Prelude.....II-35
Treatment Regimes: The Golden Rule.....II-35
1$100
   Challenges Encountered in Clinical Trials.....II-361$100
   FDA’s Antidotes.....II-371$100
   Cancer: A Definition.....II-38
Hematological Cancers.....II-38
Types of Hematological Cancer.....II-38
Multiple Myeloma.....II-38
1$100
   Multiple Myeloma Stages.....II-39
Stage I.....II-39
Stage II/III.....II-39
Treatment Procedures.....II-39
Diagnosis.....II-39
1$100
   Treatment.....II-40
Initial Treatment Regimen.....II-40
Induction Therapy for SCT Candidates.....II-40
1$100
   Induction Therapy for Non-SCT Candidates.....II-41
Therapy for Relapsed or Refractory Myeloma.....II-41
Maintenance Therapy for Relapsed or Refractory Myeloma.....II-41
Treatment Pros & Cons.....II-41
1$100
   Other Types of Hematological Cancers.....II-42
Leukemia.....II-42
Acute Lymphocytic Leukemia.....II-42
Chronic Lymphocytic Leukemia.....II-42
1$100
   Acute Myeloid Leukemia.....II-43
Chronic Myeloid Leukemia.....II-43
Lymphoma.....II-43
1$100
   Non-Hodgkin’s Lymphoma.....II-44
Hodgkin’s Lymphoma.....II-44
Myelodysplastic Syndromes.....II-44
Hematological Cancer Therapies.....II-44
Chemotherapy.....II-44
1$100
   Radiation Therapy.....II-45
Stem Cell Transplants.....II-45
1$100
   Biological Therapy.....II-46
Targeted Therapy.....II-46
Gene Therapy.....II-46
Immunotherapy.....II-46
Monoclonal Antibody Treatment.....II-46
1$100
   Vaccines.....II-47
Donor Lymphocyte Infusion.....II-47
Hematological Cancer Drug Classes.....II-47
Hypomethylating Agents & Antimetabolites.....II-47
1$100
   Bisphosphonates.....II-48
Alkylating Agents and DNA-Damaging Agents.....II-48
DNA-Repair Enzyme Inhibitors.....II-48
Histone Deacetylase Inhibitor.....II-48
Immunomodulators.....II-48
Proteasome Inhibitor.....II-48
Tyrosine Kinase Inhibitors.....II-48
1$100
   Celgene Launches Revlimid and Lenadex Drugs in Japan.....II-49
Millennium Receives FDA Approval for Supplemental NDA of VELCADE.....II-49
Intas Introduces Bortezomib Injection for Treating Multiple Myeloma in India.....II-49
NICE Grants Approval for Use of Revlimid®.....II-49
1$100
   SWOG Announces Closure of Phase III Trial (S0232) for Paitents with Multiple
  Myeloma.....II-50
Fujimoto Pharmaceutical Receives Approval to Market Thalidomide.....II-50
Celgene Obtains Health Canada Approval for Revlimid Oral Cancer Drug.....II-50
FDA Grants Orphan-Drug Designation to Melphalan.....II-50
1$100
   Merck Commences Phase II-b and Phase III Clinical Trial of Zolinza.....II-51
Clavis Initiates Phase II Trial of Elacytarabine.....II-51
Gilead Sciences Commences GS 9219 Phase I Clinical Trial.....II-51
AstraZeneca Carries Out AZD 0530 Phase II trial.....II-51
European Commission Grants Approval of Thalidomide for Multiple Myeloma.....II-51
1$100
   EMEA Issues Positive Opinion for Thalidomide Use in Multiple Myeloma.....II-52
Global Regulatory Developments for the Use of Revlimid® in Multiple Myeloma.....II-52
1$100
   Takeda Gains FDA Approval to Promote Velcade.....II-53
Health Canada Approves VELCADE.....II-53
Genzyme Receives FDA Certification for Mozobil.....II-53
Celgene’s Thalidomide Pharmion Receives Marketing Authorization.....II-53
1$100
   Ziopharm Commences Phase II Clinical Trial of ZIO-101.....II-54
FDA Approves Pluristem’s Pre-IND Application of PLX-I.....II-54
Merck Pharmaceuticals Commences Phase I Study for R763 Kinase Inhibitor.....II-54
Swissmedic Approves Celgene’s REVLIMID Oral Cancer Drug.....II-54
Celgene’s REVLIMID Receives EU’s Marketing Authorization.....II-54
1$100
   FDA Approves Application of Piramal’s IND-P276 Multiple Myeloma Drug.....II-55
Millennium Pharmaceuticals and Johnson & Johnson Initiate Velcade® Phase II
  Trial.....II-55
FDA to Consider the New Drug Application Filed for Use of Doxil® Combined with Velcade®
  in Patients with Multiple Myeloma.....II-55
Ortho Biotech Files Application with FDA for Approval of Combination Drug DOXIL® and
  VELCADE®.....II-55
1$100
   Caraco’s Allopurinol Receives FDA Approval.....II-56
FDA Approves Thalomid® as Combination Therapy for Multiple Myeloma.....II-56
Revlimid® Obtains Regulatory Approval for the Treatment of Multiple Myeloma.....II-56
LymphoSign Inc. Announces Successful Completion of LS104 Drug’s Pre-Clinical
  Testing.....II-56
Seattle Genetics Commences SGN-40 Phase I Clinical Trial.....II-56
FDA Approves Use of Revlimid® for Multiple Myeloma.....II-56
1$100
   US FDA Approves Use of Thalidomide for Multiple Myeloma.....II-57
Ziopharm Oncology Receives Approval to Commence ZIO-101 and ZIO-201 Trial.....II-57
FDA Grants Approval for Use of VELCADE® for Patients with Mantle Cell Lymphoma.....II-57
1$100
   Onyx Files NDA for Carfilzomib in Myeloma Treatment.....II-58
XTL Gains Orphan Drug Designation for rHuEPO.....II-58
Signal Genetics Enters into a Commercialization Agreement with NeoGenomics
  Laboratories.....II-58
1$100
   The Leukemia & Lymphoma Society Forms Alliance with Acetylon Pharmaceuticals.....II-59
Onyx Pharmaceuticals Gains FDA Fast Track Designation for Carfilzomib.....II-59
MMRF Enters into Collaboration with Astellas Pharma.....II-59
Takeda and Millennium Submit Two sNDA to FDA for Bortezomib.....II-59
Astex Enters into Definitive Merger Agreement with SuperGen.....II-59
1$100
   Yakult Honsha Enters into an Agreement with Aeterna Zentaris.....II-60
Celgene Submits MAA for REVLIMID in Europe.....II-60
BMS Halts Tanespimycin Development.....II-60
1$100
   Acetylon Releases Pre-Clinical Data for ACY-1215 in Multiple Myeloma.....II-61
Intellikine and MMRC Initiate Phase I Clinical Trial of INK128.....II-61
Celgene Gains MHLW Approval for REVLIMID in Japan.....II-61
XTL Acquires Bio-Gal.....II-61
1$100
   Compugen Discovers New Drug Target for Treating Multiple Myeloma.....II-62
Boehringer Ingelheim Enters into a Collaboration Agreement with Micromet.....II-62
Abbott Acquires Facet Biotech.....II-62
1$100
   Mannkind Enters Into a Research Agreement with MMRF.....II-63
Genentech Terminates Collaboration Agreement with Seattle for SGN-40.....II-63
Keryx Gains Fast Track Designation for Perifosine from FDA.....II-63
1$100
   FDA Clears Perifosine for Phase III Clinical Trials in Multiple Myeloma.....II-64
CyDex Receives FDA Approval for Clinical Evaluation of CDX-353.....II-64
Onyx Acquires Proteolix.....II-64
1$100
   Johnson & Johnson to Acquire Cougar.....II-65
Janssen and Takeda Ink Co-Promotion Agreement.....II-65
Eisai Establishes Subsidiary in Canada.....II-65
Roche Group and ImmunoCellular Therapeutics Ink Licensing Agreement.....II-65
1$100
   CytRx Acquires Innovive.....II-66
Launch of Epoetin alfa Hexal.....II-66
PDL and Bristol-Myers Signs Agreement.....II-66
MNKD and LLS Conclude Joint Research Agreement.....II-66
1$100
   MorphoSys and DSM Enter into Agreement.....II-67
StemCyte Enters into Joint Venture with Cadila and Apollo Hospitals in India.....II-67
ImmunoCellular Acquires Molecular Antibody Technology.....II-67
US House of Representatives Sanction the Hematological Cancer Research Investment
  and Education Act.....II-67
1$100
   Bayer and Cell Therapeutics Enter into Mutual Agreement.....II-68
Bristol-Myers Takes Over Kosan Biosciences.....II-68
Bristol and PDL BioPharma Enter into Agreement.....II-68
Gamida Cell Enters Into a Agreement with Amgen.....II-68
1$100
   Circadian Acquires Complete Stake in Vegenics.....II-69
Takeda Acquires Millennium Pharmaceuticals.....II-69
Access Pharmaceuticals Acquires Somanta.....II-69
Celgene Acquires Pharmion.....II-69
1$100
   GlaxoSmithKline Forms Alliance with OncoMed for Developing Cancer Therapeutics.....II-70
Cyclacel Acquires ALIGN Pharmaceuticals.....II-70
Biogen and Genentech to Jointly Develop and Commercialize New Blood Cancer
  Drug.....II-70
1$100
   Aegera Therapeutics Acquires LymphoSign Inc.....II-71
Velcade Gains Subsidy.....II-71
Inex Pharmaceuticals Spins Off Biotechnology Business into Tekmira
  Pharmaceuticals.....II-71
MilleGen Enters into Collaboration with LFB.....II-71
1$100
   TopoTarget Acquires Apoxis SA.....II-72
Genentech Inks Exclusive Global Licensing Agreement with Seattle Genetics.....II-72
PerkinElmer Takes Over ViaCell.....II-72
Favrille Announces Acquisition of Monoclonal Antibody Range from Diversa.....II-72
1$100
   Johnson & Johnson Secures Contract worth US$112 Million.....II-73
Bioniche Pharma Acquires Branded Pharmaceutical from Nabi Biopharmaceuticals.....II-73
Takara Bio's RetroNect Used for Clinical Trials of Gene Therapy in Australia.....II-73
MDS Pharma Services Becomes Recommended CRO for Multiple Myeloma Drug R&D.....II-73
1$100
   Celgene Certifies McKesson Specialty to Launch Revlimid.....II-74
Medarex and PacMab to Co-Develop Blood Cancer Therapies.....II-74
Gamida Cell and Teva to Co-Develop Therapy for Hematological Malignancies.....II-74
GlaxoSmithKline Takes Over Praecis Pharmaceuticals.....II-74
Biotest Acquires ImmunoGen Anticancer Technology Rights.....II-74
1$100
   Hana Signs Licensing Agreement with Inex.....II-75
Cephalon Acquires Zeneus.....II-75
1$100
   Amgen, Inc. (USA).....II-76
Bristol-Myers Squibb Company (USA).....II-76
Celgene Corporation (USA).....II-76
F. Hoffmann-La Roche Ltd (Switzerland).....II-76
1$100
   Genentech, Inc. (USA).....II-77
Janssen Biotech, Inc. (USA).....II-77
Millennium Pharmaceuticals (USA).....II-77
Seattle Genetics (USA).....II-77
1$100
   Ziopharm Oncology, Inc. (USA).....II-781$100
   Table 8: World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-791$350
   Table 9: World Historic Review for Multiple Myeloma Therapeutics by Geographic Region – US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-801$350
   Table 10: World 15-Year Perspective for Multiple Myeloma Therapeutics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World Markets for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-811$350
   A. Market Analysis.....II-82
Current & Future Analysis.....II-82
US Myeloma Statistics.....II-82
Table 11: Multiple Myeloma Disease Statistics in the US: 2010 (includes corresponding Graph/Chart).....II-82

Table 12: Addressable Multiple Myeloma Patient Population in the US by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-82
1$350
   Table 13: Hematological Malignancies in the US (2009): Number of Incidences by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart).....II-831$350
   Table 14: Hematological Malignancies in the US (2009): Number of Deaths by Type of Cancer - Lymphoma (Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma), Multiple Myeloma, Leukemia (Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, and Other Leukemia) (includes corresponding Graph/Chart).....II-84

Table 15: Blood Cancer Statistics in the US (2010): Percentage Breakdown of Hematological Cancer Cases by Type: Lymphoma, Myeloma, and Leukemia (includes corresponding Graph/Chart).....II-84
Trends in Myeloma Therapeutics in the US.....II-84
Doctors Shift to Continuous Therapy in Myeloma Treatment.....II-84
1$350
   Table 16: Key Drug Regimens in the US Multiple Myeloma Market (2006): Breakdown of Typical Length of Treatment Cycle and Cost per Cycle (In US$) (includes corresponding Graph/Chart).....II-851$350
   Market Share Statistics.....II-86
Table 17: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-86

Table 18: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the US in Relapsed/Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-86

Table 19: US Market for Multiple Myeloma Therapeutics (2010): Percentage Market Share Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-86
Key Non-Profit Organizations in the US.....II-86
1$350
   Multiple Myeloma Research Foundation (MMRF).....II-87
National Coalition for Cancer Survivorship (NCCS).....II-87
National Marrow Donor Program (NMDP).....II-87
Oregon Health and Science University Cancer Institute.....II-87
Drug Approvals.....II-87
1$100
   Strategic Corporate Developments.....II-885$150
   Focus on Select Key Players.....II-933$125
   B. Market Analytics.....II-96
Table 20: The US Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-96
1$350
   Table 21: US Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-971$350
   A. Market Analysis.....II-98
Current & Future Analysis.....II-98
Myeloma in Japan.....II-98
Table 22: Multiple Myeloma Disease Statistics in Japan: 2010 (includes corresponding Graph/Chart).....II-98

Table 23: Addressable Multiple Myeloma Patient Population in Japan by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-98
Drug Launches.....II-98
1$350
   Strategic Corporate Developments.....II-991$100
   B. Market Analytics.....II-100
Table 24: Japanese Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-100
1$350
   Table 25: Japanese Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1011$350
   A. Market Analysis.....II-102
Current & Future Analysis.....II-102
Myeloma in the EU – A Statistical Review.....II-102
Table 26: Multiple Myeloma Disease Statistics in the EU: 2010 (includes corresponding Graph/Chart).....II-102

Table 27: Addressable Multiple Myeloma Patient Population in the EU by Treatment Stage: 2010 (includes corresponding Graph/Chart).....II-102

Table 28: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in First Line Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-102
1$350
   Table 29: Market Share Breakdown of Major Multiple Myeloma Drug Regimens in the EU in Relapsed/Refractory Setting by Number of Patients on Treatment: 2010 (includes corresponding Graph/Chart).....II-103
Europe Lagging Behind in Drug Approvals.....II-103
Thalidomide Takes Rebirth in the UK NHS.....II-103
Strategic Corporate Developments.....II-103
1$350
   F. Hoffmann-La Roche Ltd (Switzerland) – A Key Player.....II-1041$100
   B. Market Analytics.....II-105
Table 30: European Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-105
1$350
   Table 31: European Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1061$350
   A. Market Analysis.....II-107
Current & Future Analysis.....II-107
Strategic Corporate Developments.....II-107
1$100
   Drug Launch.....II-1081$100
   B. Market Analytics.....II-109
Table 32: Rest of World Recent Past, Current & Future Analysis for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-109
1$350
   Table 33: Rest of World Historic Review for Multiple Myeloma Therapeutics Market Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1101$350
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com